interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Metoprolol Succinate

Generic competition · all medicines · read 12 November 2026

Is there a generic of Metoprolol Succinate, and who makes it?

Metoprolol Succinate appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 17 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 14.6 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Metoprolol Succinate2 dosage-form groups in the Orange Book
17generic makers listed
  1. Metoprolol Succinate appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 17 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came 14.6 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Extended Release, Oral

Four or more generic makers listed

Brand listed as marketed: Toprol-Xl. 17 generic makers with 60 generic products listed as marketed; the first generic approval is dated 31 July 2006.

199019952000200520102015202020252030017brand 1992Actavis Laboratories Fl Inc, first approval 3 August 2009Wockhardt Bio Ag, first approval 22 July 2010Dr Reddys Laboratories Ltd, first approval 1 August 2012Doctor Reddys Laboratories Ltd, first approval 15 August 2012Actavis Elizabeth Llc, first approval 25 November 2016Novast Laboratories Ltd, first approval 6 February 2018Zydus Pharmaceuticals Usa Inc, first approval 23 March 2018Cipla Ltd, first approval 26 October 2018Visum Pharmaceutical Co Ltd, first approval 19 December 2018Alicora Inc, first approval 30 March 2020Hetero Labs Ltd Unit Iii, first approval 6 November 2020Alkem Laboratories Ltd, first approval 25 November 2020Yichang Humanwell Pharmaceutical Co Ltd, first approval 12 February 2021Sunshine Lake Pharma Co Ltd, first approval 26 September 2022Granules India Ltd, first approval 12 June 2023Zhejiang Jutai Pharmaceutical Co Ltd, first approval 26 July 2024Ipca Laboratories Ltd, first approval 25 June 2025data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Actavis Laboratories Fl Inc3 August 20091
Wockhardt Bio Ag22 July 20104
Dr Reddys Laboratories Ltd1 August 20122
Doctor Reddys Laboratories Ltd15 August 20122
Actavis Elizabeth Llc25 November 20164
Novast Laboratories Ltd6 February 20184
Zydus Pharmaceuticals Usa Inc23 March 20184
Cipla Ltd26 October 20183
Visum Pharmaceutical Co Ltd19 December 20184
Alicora Inc30 March 20204
Hetero Labs Ltd Unit Iii6 November 20204
Alkem Laboratories Ltd25 November 20204

5 more makers are listed in the data.

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Capsule, Extended Release, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Kapspargo Sprinkle. No generic is listed as marketed.

2015202020252030203501brand 2018data datePatent 9504655 listed to expire 9 July 2035Patent 9700530 listed to expire 9 July 2035
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 9 July 2035Patent 9504655 drug product
  • 9 July 2035Patent 9700530 drug product

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.